Receptors, Thrombopoietin
"Receptors, Thrombopoietin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cell surface receptors that are specific for THROMBOPOIETIN. They contain two central FIBRONECTIN TYPE III DOMAINS and signal through interaction with JANUS KINASES such as JANUS KINASE 2.
| Descriptor ID |
D053628
|
| MeSH Number(s) |
D12.776.543.750.705.852.610
|
| Concept/Terms |
Receptors, Thrombopoietin- Receptors, Thrombopoietin
- Thrombopoietin Receptors
- CD110 Antigens
- MPL Ligand Receptor
- Thrombopoietin Receptor
- Antigens, CD110
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Thrombopoietin".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Thrombopoietin".
This graph shows the total number of publications written about "Receptors, Thrombopoietin" by people in this website by year, and whether "Receptors, Thrombopoietin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Thrombopoietin" by people in Profiles.
-
Whole-genome CRISPR screening identifies N-glycosylation as a genetic and therapeutic vulnerability in CALR-mutant MPNs. Blood. 2022 09 15; 140(11):1291-1304.
-
Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. Mod Pathol. 2021 01; 34(1):20-31.
-
Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN. Blood. 2018 02 15; 131(7):782-786.
-
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy. Br J Haematol. 2017 09; 178(6):906-913.
-
Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. Cancer Discov. 2016 Apr; 6(4):368-81.
-
Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition. Nat Med. 2015 Dec; 21(12):1473-80.
-
Detection of MPL mutations by a novel allele-specific PCR-based strategy. J Mol Diagn. 2013 Nov; 15(6):810-8.
-
The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol. 1995 Aug; 23(9):1040-8.